Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa dose-finding study of MIT-001 to prevent oral mucositis in lymphoma or multiple myeloma patients undergoing autologous HSCT
KCT0006696Phase 2Completed
- Sponsor
- MitoImmune Therapeutics
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LC28-0126 in stomatitis, sponsored by MitoImmune Therapeutics. Started Feb 2022; status: completed.
02
Drugs
LC28-0126
03
Conditions
stomatitis
Beyond the preview
Go deeper on KCT0006696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006696.